A Phase 1 Study of ASP4070 to Confirm Safety and Immunological Response in Patients With Cedar Pollinosis When Administered as Intramuscular (IM) Vaccination and Intradermal (ID) Vaccination

Trial Profile

A Phase 1 Study of ASP4070 to Confirm Safety and Immunological Response in Patients With Cedar Pollinosis When Administered as Intramuscular (IM) Vaccination and Intradermal (ID) Vaccination

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Sep 2016

At a glance

  • Drugs ASP 4070 (Primary) ; ASP 4070 (Primary)
  • Indications Allergic rhinitis; Tree pollen hypersensitivity
  • Focus Adverse reactions
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 14 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 17 Aug 2015 According to the ClinicalTrials.gov record, status changed from not yet recruiting to active, no longer recruiting.
    • 17 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top